Company: HCTI
Filing Date: 2025-11-28
Form Type: S-3
Source: 0001213900-25-115888
Chunk: 3

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-28
Form: S-3
Chunk 3
---
, agents or broker-dealers on terms to be determined
at the time of sale, as described in more detail in this prospectus. See “Plan of Distribution” beginning on page 16 of this
prospectus for more information about how the Selling Stockholders may sell their respective shares of Common Stock. The Selling Stockholders
may be deemed “underwriters” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended. (the “Securities
Act”).

We have agreed, pursuant to
the terms of the Registration Rights Agreement, to bear all of the expenses in connection with the registration of the Conversion Shares
pursuant to this prospectus. The Selling Stockholders will pay or assume all commissions, discounts, fees of underwriters, agents, selling
brokers or dealer managers and similar expenses, if any, attributable to their respective sales of the shares of Common Stock.

Our Common Stock is listed
on the Nasdaq Capital Market under the symbol “HCTI”. On November 21, 2025, the closing price of our Common Stock on the Nasdaq
Capital Market was $1.91 per share.

This offering will terminate on the earlier of (i) the date when all of the securities registered hereunder have been sold pursuant to this prospectus or Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), and (ii) the date on which all of such securities may be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, unless we terminate it earlier.

Investing in our Common Stock involves risks. You should carefully review the risks described under the heading “Risk Factors” beginning on page 12 and in the documents which are incorporated by reference herein before you invest in our Common Stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. Currently, we are an “emerging growth company” as defined in Section 2(a) of the Securities Act of 1933, as amended, and are subject to reduced public company reporting requirements. Please read “Implications of Being an Emerging Growth Company.”

<div align='center'>The date of this prospectus is [●], 2025

TABLE OF CONTENTS</div>

|                                                                                   | Page |
| ABOUT THIS PROSPECTUS                                                             |   ii |
|